The PoCCardio project is a 60 month Research and Innovation Action (RIA) co-funded by the European Commission through the Horizon Europe Framework Programme for Research and Innovation as part of the Personal Health Systems objective.
Myocardial infarction (MI) remains a major cause of morbidity and mortality in Europe and the United States. Despite available tools for risk stratification and the availability of a variety of drugs and treatment approaches to lower cardiovascular (CV) risk, the incidence of recurrent CV events remains high in subjects with previous MI. The PoCCardio partners are proposing a set of CV biomarkers that have repeatedly emerged as predictors of CV event risk, either alone, or even more convincingly in various combinations.
The PoCCardio project thus aims to promote personalised treatment of Cordio Vascular Diseases (CVD) by identification of ‘extremely high risk’ subjects using biomarkers and to explore the potential of multifactorial intensified risk factor treatment in lowering CV risk and recurrent events. The project will develop an innovative Lab-on-Chip (LoC) device that allows rapid and low-cost point-of-care (PoC) measurements of both proteomic biomarkers and genetic risk variants, and 2) validate accuracy, sensitivity, specificity and feasibility of the PoC device.
The PoCCardio device brings together biomarker measurement and profiling of genetic variations, and thus will be used to enhance risk stratification and to provide the affected individuals with personalised care. It also limits the amount of both expensive reagents and blood samples needed for the tests, and thus reduces both cost and patient’s pain and discomfort.
A PoC device, developed within the H2020 PoCOsteo project, will be further developed and tailored to provide a self-contained and portable method of analysing blood samples from patients at the treating sites. Disposable microfluidic cartridges will enable contamination-free sample collection via a user-friendly blood collection method (e.g., capillary) as well as in-device sample preparation overcoming the need for trained personnel and multi-step tests.
The clinical validation of the qualified biomarkers and the PoC tool itself, will be performed in a prospective, randomised multinational trial, including only existing and approved pharmaceuticals. The trial will provide the scientific foundation to support regulatory authorities regarding approval of companion diagnostics, and recommendations for the prescription of drugs, respectively.